Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567547 | 0.85 | APLNR (0.69) | APLNRHTR2AHTR2CHDAC3HDAC1 | |
| SCHEMBL783785 | 0.85 | APLNR (1.00) | APLNRHTR2AHTR2CHDAC3HDAC1 | |
| SCHEMBL20565545 | 0.83 | POLB (0.52) | APLNRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL6099643 | 0.82 | APLNR (0.80) | APLNRHTR2AHTR2CHDAC3HDAC1 | |
| SCHEMBL7768853 | 0.82 | APLNR (0.86) | APLNRHTR2AHTR2CHDAC3HDAC1 | |
| SCHEMBL13596595 | 0.81 | APLNR (0.63) | APLNRHTR2AHTR2CHDAC3HDAC1 | |
| SCHEMBL712690 | 0.81 | APLNR (0.72) | APLNRHTR2AHTR2CHDAC3HDAC1 | |
| SCHEMBL12522890 | 0.80 | APLNR (0.83) | APLNRHTR2AHTR2CHDAC3HDAC1 | |
| SCHEMBL24817719 | 0.80 | APLNR (0.65) | APLNRHTR2AHTR2CHDAC3HDAC1 | |
| SCHEMBL18964965 | 0.80 | APLNR (0.65) | APLNRHTR2AHTR2CHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-10829500-B2 | Pyridyl-triazabicycles | HOFFMANN-LA ROCHE INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190352312-A1 | PYRIDYL-TRIAZABICYCLES | HOFFMANN-LA ROCHE INC. | 2019-11-21 | — | — | US | disclosed |
| US-10414780-B2 | Pyridyl-triazabicycles | HOFFMANN-LA ROCHE INC. (US) | 2019-09-17 | — | — | US | disclosed |
| EP-3172206-B1 | PYRIDYL-TRIAZABICYCLES | HOFFMANN LA ROCHE (CH) | 2019-01-30 | — | — | EP | disclosed |
| US-20180312528-A1 | PYRIDYL-TRIAZABICYCLES | HOFFMANN-LA ROCHE INC. | 2018-11-01 | — | — | US | disclosed |
| US-20180194779-A1 | PYRIDYL-TRIAZABICYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-07-12 | — | — | US | disclosed |
| EP-2233474-B1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-8946211-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| WO-2007020190-A1 | FLUORO SUBSTITUTED 2-OXO AZEPAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007020190-A1 | FLUORO SUBSTITUTED 2-OXO AZEPAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037789-A1 | 4-chloro-N-((R)-5,5-difluoro-2-oxo-azepan-3-yl)-N-[2-fluoro-4-(2H-[1,2,4]triazol-3-yl)-benzyl]-benzenesulfonamide; gamma -secretase inhibitor; neurodegenerative diseases; Alzheimer's disease; anticarcinogenic agent; cervical carcinomas and breast carcinomas and malignancies of the hematotic system | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070037789-A1 | 4-chloro-N-((R)-5,5-difluoro-2-oxo-azepan-3-yl)-N-[2-fluoro-4-(2H-[1,2,4]triazol-3-yl)-benzyl]-benzenesulfonamide; gamma -secretase inhibitor; neurodegenerative diseases; Alzheimer's disease; anticarcinogenic agent; cervical carcinomas and breast carcinomas and malignancies of the hematotic system | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070037789-A1 | 4-chloro-N-((R)-5,5-difluoro-2-oxo-azepan-3-yl)-N-[2-fluoro-4-(2H-[1,2,4]triazol-3-yl)-benzyl]-benzenesulfonamide; gamma -secretase inhibitor; neurodegenerative diseases; Alzheimer's disease; anticarcinogenic agent; cervical carcinomas and breast carcinomas and malignancies of the hematotic system | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-08-03 | — | — | US | disclosed |
| EP-1626961-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-02-22 | — | — | EP | disclosed |
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | US | disclosed |
| WO-2006005486-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| WO-2004101523-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352312-A1 | PYRIDYL-TRIAZABICYCLES | BACE1, BACE2, PSEN1 | APLNR 2405/4885HTR2A 1262/4885HTR2C 1741/4885 |
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | BACE1, APP, BACE2 | APLNR 79/4885HTR2A 904/4885HTR2C 1353/4885 |
| US-20180194779-A1 | PYRIDYL-TRIAZABICYCLES | BACE1, BACE2, PSEN1 | APLNR 2361/4885HTR2A 1306/4885HTR2C 1909/4885 |
| US-10414780-B2 | Pyridyl-triazabicycles | BACE1, BACE2, PSEN1 | APLNR 2405/4885HTR2A 1262/4885HTR2C 1741/4885 |
| US-20070037789-A1 | 4-chloro-N-((R)-5,5-difluoro-2-oxo-azepan-3-yl)-N-[2-fluoro-4-(2H-[1,2,4]triazol-3-yl)-benzyl]-benzenesulfonamide; gamma -secretase inhibitor; neurodegenerative diseases; Alzheimer's disease; anticarcinogenic agent; cervical carcinomas and breast carcinomas and malignancies of the hematotic system | BACE1, BACE2, BRCA1 | APLNR 918/4885HTR2A 2589/4885HTR2C 1959/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | APLNR 1931/4885HTR2A 3539/4885HTR2C 2713/4885 |
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | MALT1, BRCA1, MCL1 | APLNR 2201/4885HTR2A 3255/4885HTR2C 2064/4885 |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | APLNR 272/4885HTR2A 50/4885HTR2C 43/4885 |
| US-10829500-B2 | Pyridyl-triazabicycles | BACE1, BACE2, PSEN1 | APLNR 2405/4885HTR2A 1262/4885HTR2C 1741/4885 |
| US-20180312528-A1 | PYRIDYL-TRIAZABICYCLES | BACE1, BACE2, PSEN1 | APLNR 2405/4885HTR2A 1262/4885HTR2C 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.